High-purity chemical intermediates and APIs serving the European biotech cluster.
As a leading Anticancer Drugs Manufacturer & Supplier in Berlin, we recognize the city's role as a powerhouse in the European life sciences sector. Berlin is home to one of Europe's largest biotechnology clusters, the "HealthCapital Berlin-Brandenburg." This ecosystem integrates world-class research institutions like the Charité - Universitätsmedizin Berlin with agile manufacturing firms, creating a unique environment for oncological innovation.
Berlin-Adlershof is Germany's leading science and technology park. Our strategic alignment with the scientific standards of this region ensures that our anticancer APIs meet the rigorous requirements of German pharmaceutical research.
The trend in Berlin's industrial landscape is shifting toward personalized oncology. We supply localized laboratories with high-purity intermediates that facilitate the development of targeted therapies.
Utilizing Berlin’s central European location, our supply chain ensures rapid distribution of critical raw materials like Tacrolimus and Cabozantinib across the EU, adhering to GDP (Good Distribution Practice) standards.
In Berlin, the synergy between academic research (such as the Max Delbrück Center for Molecular Medicine) and commercial manufacturing has catalyzed a surge in demand for high-quality chemical intermediates. Our role as a supplier is to bridge the gap between initial lab-scale synthesis and industrial-scale production. We specialize in small-molecule kinase inhibitors and cytotoxic agents that form the backbone of modern chemotherapy and targeted drug regimens.
The pharmaceutical industry in Berlin and globally is undergoing a digital transformation. The integration of AI in drug discovery and the synthesis of anticancer drugs is no longer a futuristic concept—it is the current standard. As a forward-thinking supplier, we utilize AI-driven data analytics to optimize our manufacturing processes, ensuring that every batch of Dasatinib or Ibrutinib meets exact molecular specifications.
Localized application scenarios in Berlin often involve clinical trials conducted at the Charité. These trials require highly specialized, small-batch intermediates that large-scale global manufacturers often overlook. We fill this niche by providing custom manufacturing services (CMO) that cater specifically to the European R&D sector.
Hangzhou Jeci Biochem Technology Co., Ltd. is located in Hangzhou, Zhejiang Province. We are committed to sales of active pharmaceutical ingredients, pharmaceutical intermediates, nutritional products and food additives, cooperative R & D, custom manufacturing, sales and service as well as import of these kinds of materials.
In China, we have a strong collaborative R&D team, working in depth with new drug research institutes and multiple custom processing plants. We have very good domestic sales channels and have long-term relationships with domestic companies, including product applications, technology transfer, product supply, custom processing, and exclusive agents for multiple products in multiple regions. In addition, we also provide factory quality management system certification consulting services.
Internationally, we have long-term trade relations with India, Southeast Asia, South Korea, Japan, and European markets such as Berlin, Germany. We provide products in the whole process of market and sales services. At the same time, we also provide product registration, consulting and sales channel expansion services for overseas companies in the Chinese market.
Drugs and intermediates are widely used in the following aspects (partial):
Production Equipment: We are able to assemble and produce larger quantities of intermediates and provide some advanced, convenient manufacturing capabilities, including batch processing and customization.
For the company's main product intermediates: We can maximize our advantages, meet the requirements of most customers and complete the task within the specified time limit. Our infrastructure is designed to support the high-tech demands of the Berlin pharmaceutical industry.
Premium supply of APIs for localized Berlin research and commercial applications.
The products listed above, such as Cabozantinib and Trametinib, represent the pinnacle of kinase inhibitor technology. In the Berlin clinical landscape, these compounds are vital for treating renal cell carcinoma, non-small cell lung cancer (NSCLC), and melanoma. Our synthesis process focuses on polymorphic stability and particle size distribution (PSD), which are critical for the bioavailability of oral oncology drugs.
By maintaining a robust supply line to Berlin, we support the local "Bench to Bedside" initiative, ensuring that researchers have immediate access to high-purity raw materials. Our commitment to excellence mirrors the precision engineering for which Germany is famous.
SJ medical
